HC Wainwright & Co. Maintains Buy on Janux Therapeutics, Raises Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a Buy rating on Janux Therapeutics (NASDAQ:JANX) and raises the price target from $35 to $50.
March 11, 2024 | 10:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Janux Therapeutics and increases the price target from $35 to $50.
The upgrade in the price target from $35 to $50 by a reputable analyst firm like HC Wainwright & Co. signals strong confidence in Janux Therapeutics' future performance. This positive outlook is likely to influence investor sentiment and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100